CCT for Comprehensive Risk Stratification Following STEMI - Trial NCT06020209
Access comprehensive clinical trial information for NCT06020209 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Turin, Italy and is currently Recruiting. The study focuses on Myocardial Infarction. Target enrollment is 200 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Turin, Italy
Timeline & Enrollment
N/A
Sep 01, 2023
Apr 30, 2026
Primary Outcome
CCT - diagnostic accuracy,CCT - risk stratification,CCT - Coronary artery disease (CAD) impact of risk stratification
Summary
The CT-STEMI study aims to evaluate a comprehensive cardiac computed tomography (CCT)
 protocol for assessing the risk of heart failure (HF), life-threatening arrhythmias (LTA),
 and atherothrombotic events following ST-elevation myocardial infarction (STEMI). This
 multicenter, prospective study has three main objectives:
 
 1. Comparing the diagnostic accuracy of the comprehensive CCT protocol with cardiac
 magnetic resonance (CMR), considered the non-invasive gold standard.
 
 2. Determining the prognostic value of CCT in assessing myocardial tissue adverse features
 related to STEMI.
 
 3. Evaluating the atherosclerotic burden in patients with post-acute STEMI.
 
 Two hundred patients will undergo both CCT and CMR in the post-acute phase, and their
 follow-up will focus on monitoring HF, LTA, and ischemic events. The CT-STEMI study
 represents the first attempt to assess the potential of CCT in providing a comprehensive risk
 assessment following STEMI in a large contemporary population. The findings of this study
 have the potential to revolutionize post-STEMI risk stratification practices.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06020209
Non-Device Trial